The coronavirus disease-2019 (COVID-19) pandemic has disrupted healthcare globally, including diagnostic services.1 In Türkiye, healthcare restrictions began shortly after March 11, 2020. Pulmonary function test (PFT) use, especially spirometry, declined because of concerns about transmission, which may indicate unmet healthcare needs.2 The use and quality of PFTs declined during the pandemic due to concerns about infection transmission.3
A recent nationwide study by Görek Dilektaşlı et al.4 highlighted substantial reductions in PFT practices and variability in adherence to safety protocols across Türkiye during the pandemic. We conducted a study reviewing trends in the use of PFTs before, during, and after the COVID-19 pandemic in the outpatient pulmonology clinic of a university hospital.
This retrospective, cross-sectional, single-center study reviewed outpatient visits and the number of PFTs performed at the Ankara University Hospital Chest Diseases Department from May 1, 2019, to December 31, 2024. Data were grouped into pre-pandemic (pre-COV), before the World Health Organization’s declaration of the global pandemic on March 11, 2020; pandemic (COV), until the official end of the emergency status on May 31, 2023; and post-pandemic (post-COV), through December 31, 2024. The PFT laboratory data included monthly totals for spirometry, lung volumes measured by the multiple-breath nitrogen washout method and by body plethysmography, and carbon monoxide diffusing capacity. Monthly counts of new COVID-19 cases were extracted from online open data sources.5 Data were summarized as mean ± standard deviation or median [25th–75th percentiles], with normality assessed by the Shapiro-Wilk test and by visual inspection. ANOVA or Kruskal-Wallis tests were used for comparisons. Statistical analyses were performed using SPSS v27; significance was set at P < 0.05.
The mean monthly number of outpatient clinic admissions (P < 0.001), the median monthly number of spirometry tests (P < 0.001), the median monthly number of diffusing lung capacity measurements (P < 0.001), and the mean monthly number of lung volume measurements (P < 0.001) all varied significantly. The spirometry-to-outpatient-admission ratio differed significantly (P < 0.001), while no significant difference was observed between the pre-COV and post-COV periods (P = 0.19) (Table 1). A comparison of the spirometry-to-admission ratio across the periods is illustrated in Figure 1. Trends in cases and healthcare statistics over time are shown in Figure 2.
Our findings demonstrated a reduction in the use of PFTs, consistent with previous studies. One study reported an 88% drop during the pandemic; another study from Türkiye noted fewer spirometry tests in 2021 than in 2019; and a recent study found that 73% of PFT laboratories suspended testing during the first pandemic peak, with some restricting procedures such as diffusing capacity tests.3, 4, 6 As recommended in consensus reports, spirometry testing was restricted to reduce the risk of transmission, which likely contributed to this outcome.
Limitations include the single-center design, which limits generalizability, and potential confounders such as seasonal variation. The shorter pre-COV period results from missing data. The data lacked patient characteristics, such as new- or follow-up status, and did not indicate whether follow-ups were missed or diagnoses were delayed.
This study found a slight but comparable decline in PFTs during the post-pandemic period, consistent with previous reports.3 The relatively modest decline in lung diffusion capacity testing may be explained by its essential role in diagnosing certain diseases, such as interstitial lung disease, and by its link to insurance reimbursement.
In conclusion, spirometry use per outpatient admission declined significantly during the pandemic, while the spirometry-to-visit ratio showed a slight reduction from pre-COV to post-COV. This trend reflects the pandemic’s broader impact on healthcare utilization and highlights a potential unmet need. Future efforts should focus on developing safe, resilient testing strategies to ensure continuity of care during public health crises.
